An Open-Label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Trial Profile

An Open-Label, Multicenter Phase II Study to Compare the Efficacy and Safety of RAD001 as First-Line Followed by Second-Line Sunitinib Versus Sunitinib as First-Line Followed by Second-Line RAD001 in the Treatment of Patients With Metastatic Renal Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 03 May 2017

At a glance

  • Drugs Everolimus (Primary) ; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms RECORD-3
  • Sponsors Novartis
  • Most Recent Events

    • 18 Feb 2017 Results (n=128) assessing tumor genomic analysis presented at the 2017 Genitourinary Cancers Symposium.
    • 12 Feb 2017 Results of final overall survival analysis (Data cut off June 16, 2014) assessing prognostic value of various biomarkers and safety, published in the Annals of Oncology
    • 07 Jun 2016 Results of predictive biomarker analysis (n=468) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top